{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:03:23Z","timestamp":1790701403226,"version":"4.1.0"},"reference-count":50,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Schol Ed)"],"abstract":"<jats:p>Background: Several studies have demonstrated a worse prognosis in BRCA1 (BRCA1 DNA repair associated)- and BRCA2 (BRCA2 DNA repair associated)-mutated prostatic adenocarcinomas, including shorter disease-free survival, an increased risk of disease progression, and inferior overall survival. This study presents a comparative clinicopathologic analysis of grade-matched BRCA1\/2-mutant and wild-type prostatic adenocarcinomas. Materials and Methods: Cases of prostatic adenocarcinoma that underwent broad-panel next-generation sequencing (NGS) and were found to harbor BRCA1 and\/or BRCA2 mutations were retrieved from the pathology archives. The control group consisted of age, Gleason grade group, and stage-matched prostatic adenocarcinomas negative for BRCA1 and\/or BRCA2 mutations. The hematoxylin and eosin (H&amp;E) slides from both cohorts were retrieved and reviewed. The presence and location of metastasis were also recorded. The NGS data were reviewed, and the reported BRCA1 and BRCA2 variants were analyzed. Statistical analysis was performed using IBM SPSS 26 software for Windows, version 26.0 (IBM Corp., Armonk, NY, USA). Results: Histological review of the two groups showed a similar distribution of intraductal carcinoma, neuroendocrine differentiation, perineural invasion, necrosis, extraprostatic extension, and metastatic disease. Cribriform pattern was present in all BRCA-mutated cases in the study cohort, but was completely absent in the control group (p = 0.022). The BRCA1 variants were identified in three cases (30%) and included one splice-site variant, one frameshift variant, one nonsense variant, and one missense variant. The nonsense mutation was predicted to disrupt molecular recognition features, amidation, calcium binding, catalytic sites, and carboxylation (p &lt; 0.01). In contrast, BRCA2 variants were identified in nine cases, including three cases with BRCA2 loss, one case with a large genomic rearrangement involving introns 16 and 18, three cases with missense variants and two cases with frameshift variants. The two frameshift variants showed similar predicted disruption of protein function with significant impact on protein\u2013protein interaction hotspots, catalytic sites, iron binding, and sulfation (p = 0.01). Conclusion: The current study found that prostatic adenocarcinoma with cribriform morphology may be enriched for BRCA alterations and could be used to prioritize BRCA mutation testing, pending validation in larger cohorts. Mutation Prediction for Loss-of-Function (MutPred-LOF) algorithmic prediction of molecular mechanisms of pathogenicity identified variants that may impact catalytic sites, ion binding, and post-translational chemical modifications in this subgroup of BRCA-mutated prostatic adenocarcinomas; however, further functional studies are required to confirm these findings.<\/jats:p>","DOI":"10.31083\/fbs46226","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:53Z","timestamp":1790699213000},"source":"Crossref","is-referenced-by-count":0,"title":["BRCA-Mutated Prostatic Adenocarcinoma: A Distinct Clinicopathological Subset With Frequent Cribriform Morphology Associated With Domain-Specific Alterations in Putative Protein Properties"],"prefix":"10.31083","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8413-4668","authenticated-orcid":true,"given":"Selin","family":"Kurt","sequence":"first","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-0150","authenticated-orcid":true,"given":"Kritika","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Bronx, NY 10467, USA"},{"name":"Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA: a Cancer Journal for Clinicians. 2025; 75: 485\u2013497.","DOI":"10.3322\/caac.70028"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015; 163: 1011\u20131025.","DOI":"10.1016\/j.cell.2015.10.025"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. 2016; 375: 443\u2013453.","DOI":"10.1056\/NEJMoa1603144"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487: 239\u2013243.","DOI":"10.1038\/nature11125"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Chen W, Xia W, Xue S, Huang H, Lin Q, Liu Y, et al. Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients. Frontiers in Oncology. 2022; 12: 746102.","DOI":"10.3389\/fonc.2022.746102"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU International. 2012; 109: 713\u2013719.","DOI":"10.1111\/j.1464-410X.2011.10292.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2010; 16: 2115\u20132121.","DOI":"10.1158\/1078-0432.CCR-09-2871"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer. 2008; 99: 371\u2013374.","DOI":"10.1038\/sj.bjc.6604453"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000; 55: 323\u2013327.","DOI":"10.1016\/s0090-4295(99)00471-9"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Pomerantz MM, Spis\u00e1k S, Jia L, Cronin AM, Csabai I, Ledet E, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017; 123: 3532\u20133539.","DOI":"10.1002\/cncr.30808"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2015; 33: 244\u2013250.","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl 2022. Nucleic Acids Research. 2022; 50: D988\u2013D995.","DOI":"10.1093\/nar\/gkab1049"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Research. 2019; 47: D941\u2013D947.","DOI":"10.1093\/nar\/gky1015"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nature Methods. 2010; 7: 248\u2013249.","DOI":"10.1038\/nmeth0410-248"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Research. 2001; 11: 863\u2013874.","DOI":"10.1101\/gr.176601"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581: 434\u2013443.","DOI":"10.1038\/s41586-020-2308-7"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pejaver V, Urresti J, Lugo-Martinez J, Pagel KA, Lin GN, Nam HJ, et al. Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. Nature Communications. 2020; 11: 5918.","DOI":"10.1038\/s41467-020-19669-x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Pagel KA, Pejaver V, Lin GN, Nam HJ, Mort M, Cooper DN, et al. When loss-of-function is loss of function: assessing mutational signatures and impact of loss-of-function genetic variants. Bioinformatics (Oxford, England). 2017; 33: i389\u2013i398.","DOI":"10.1093\/bioinformatics\/btx272"},{"key":"ref19","unstructured":"Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, et al. BRCA genes: BRCA 1 and BRCA 2. Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology. 2018; 23: 862\u2013866."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nature Genetics. 2014; 46: 310\u2013315.","DOI":"10.1038\/ng.2892"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Medicine. 2021; 13: 31.","DOI":"10.1186\/s13073-021-00835-9"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Ghanem A, Domchek SM. New Therapeutic Options for BRCA Mutant Patients. Annual Review of Medicine. 2025; 76: 175\u2013187.","DOI":"10.1146\/annurev-med-082523-083843"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. The Prostate. 2019; 79: 880\u2013895.","DOI":"10.1002\/pros.23795"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Angel M, Freile B, Rodriguez A, Cayol F, Manneh Kopp R, Rioja P, et al. Genomic Landscape in Prostate Cancer in a Latin American Population. JCO Global Oncology. 2024; 10: e2400072.","DOI":"10.1200\/GO.24.00072"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917\u2013921.","DOI":"10.1038\/nature03445"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Current Opinion in Pharmacology. 2005; 5: 388\u2013393.","DOI":"10.1016\/j.coph.2005.03.006"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, et al. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environmental and Molecular Mutagenesis. 2022; 63: 308\u2013316.","DOI":"10.1002\/em.22505"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Frontiers in Oncology. 2023; 13: 1159557.","DOI":"10.3389\/fonc.2023.1159557"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Bilen MA, Khilfeh I, Rossi C, Morrison L, Diaz L, Hilts A, et al. Treatment patterns for patients with BRCA1\/2-positive metastatic castration-resistant prostate cancer. The Oncologist. 2025; 30: oyae183.","DOI":"10.1093\/oncolo\/oyae183"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 2020; 382: 2091\u20132102.","DOI":"10.1056\/NEJMoa1911440"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gleason DF, Mellinger GT, Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. The Journal of Urology. 2002; 167: 953\u20138; discussion 959.","DOI":"10.1016\/S0022-5347(02)80309-3"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. The American Journal of Surgical Pathology. 1994; 18: 796\u2013803.","DOI":"10.1097\/00000478-199408000-00006"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Tryggvad\u00f3ttir L, Vidarsd\u00f3ttir L, Thorgeirsson T, Jonasson JG, Olafsd\u00f3ttir EJ, Olafsd\u00f3ttir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. Journal of the National Cancer Institute. 2007; 99: 929\u2013935.","DOI":"10.1093\/jnci\/djm005"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2009; 15: 1112\u20131120.","DOI":"10.1158\/1078-0432.CCR-08-1822"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. Journal of Medical Genetics. 2003; 40: 787\u2013792.","DOI":"10.1136\/jmg.40.10.787"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2008; 14: 2953\u20132961.","DOI":"10.1158\/1078-0432.CCR-07-5237"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. European Urology. 2015; 67: 496\u2013503.","DOI":"10.1016\/j.eururo.2014.08.007"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Taylor RA, Fraser M, Livingstone J, Espiritu SMG, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications. 2017; 8: 13671.","DOI":"10.1038\/ncomms13671"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, et al. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology. 2019; 3:  https:\/\/doi.org\/10.1200\/PO.18.00327","DOI":"10.1200\/PO.18.00327"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lozano R, Salles DC, Sandhu S, Arag\u00f3n IM, Thorne H, L\u00f3pez-Campos F, et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer (Oxford, England : 1990). 2021; 147: 74\u201383.","DOI":"10.1016\/j.ejca.2021.01.027"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, et al. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. European Urology Oncology. 2024; 7: 344\u2013354.","DOI":"10.1016\/j.euo.2023.08.004"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research : MCR. 2019; 17: 446\u2013456.","DOI":"10.1158\/1541-7786.MCR-18-0440"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"B\u00f6ttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018; 18: 8.","DOI":"10.1186\/s12885-017-3976-z"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Saporita I, Calabrese M, Poletto S, Turco F, Di Stefano RF, Caffo O, et al. Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology. Clinical Genitourinary Cancer. 2025; 23: 102255.","DOI":"10.1016\/j.clgc.2024.102255"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. International Journal of Molecular Sciences. 2021; 22: 12628.","DOI":"10.3390\/ijms222312628"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Bratt O, Loman N. Clinical Management of Prostate Cancer in Men with BRCA Mutations. European Urology. 2015; 68: 194\u2013195.","DOI":"10.1016\/j.eururo.2014.11.005"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Sun P, Li Y, Chao X, Li J, Luo R, Li M, et al. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey. BMC Cancer. 2020; 20: 994.","DOI":"10.1186\/s12885-020-07481-1"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kalb R, Mallery DL, Larkin C, Huang JTJ, Hiom K. BRCA1 is a histone-H2A-specific ubiquitin ligase. Cell Reports. 2014; 8: 999\u20131005.","DOI":"10.1016\/j.celrep.2014.07.025"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Le HP, Heyer WD, Liu J. Guardians of the Genome: BRCA2 and Its Partners. Genes. 2021; 12: 1229.","DOI":"10.3390\/genes12081229"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. Journal of Cancer. 2019; 10: 2109\u20132127.","DOI":"10.7150\/jca.30410"}],"container-title":["Frontiers in Bioscience-Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/3\/10.31083\/FBS46226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:27:02Z","timestamp":1790699222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/3\/10.31083\/FBS46226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1945-0516(26)03477-0"],"URL":"https:\/\/doi.org\/10.31083\/fbs46226","relation":{},"ISSN":["1945-0516","1945-0524"],"issn-type":[{"value":"1945-0516","type":"print"},{"value":"1945-0524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"46226"}}